These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34670266)

  • 21. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
    Koerber N; Priller A; Yazici S; Bauer T; Cheng CC; Mijočević H; Wintersteller H; Jeske S; Vogel E; Feuerherd M; Tinnefeld K; Winter C; Ruland J; Gerhard M; Haller B; Christa C; Zelger O; Roggendorf H; Halle M; Erber J; Lingor P; Keppler O; Zehn D; Protzer U; Knolle PA
    Nat Commun; 2022 Jan; 13(1):153. PubMed ID: 35013191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.
    Shan S; Luo S; Yang Z; Hong J; Su Y; Ding F; Fu L; Li C; Chen P; Ma J; Shi X; Zhang Q; Berger B; Zhang L; Peng J
    Proc Natl Acad Sci U S A; 2022 Mar; 119(11):e2122954119. PubMed ID: 35238654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
    Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
    Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
    Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
    Front Immunol; 2021; 12():795741. PubMed ID: 34925381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What the Omicron wave is revealing about human immunity.
    Willyard C
    Nature; 2022 Feb; 602(7895):22-25. PubMed ID: 35110764
    [No Abstract]   [Full Text] [Related]  

  • 27. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers.
    Vanshylla K; Fan C; Wunsch M; Poopalasingam N; Meijers M; Kreer C; Kleipass F; Ruchnewitz D; Ercanoglu MS; Gruell H; Münn F; Pohl K; Janicki H; Nolden T; Bartl S; Stein SC; Augustin M; Dewald F; Gieselmann L; Schommers P; Schulz TF; Sander LE; Koch M; Łuksza M; Lässig M; Bjorkman PJ; Klein F
    Cell Host Microbe; 2022 Jan; 30(1):69-82.e10. PubMed ID: 34973165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A highly potent antibody effective against SARS-CoV-2 variants of concern.
    Fenwick C; Turelli P; Perez L; Pellaton C; Esteves-Leuenberger L; Farina A; Campos J; Lana E; Fiscalini F; Raclot C; Pojer F; Lau K; Demurtas D; Descatoire M; Joo VS; Foglierini M; Noto A; Abdelnabi R; Foo CS; Vangeel L; Neyts J; Du W; Bosch BJ; Veldman G; Leyssen P; Thiel V; LeGrand R; Lévy Y; Trono D; Pantaleo G
    Cell Rep; 2021 Oct; 37(2):109814. PubMed ID: 34599871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and Validation of Peptides Specifying SARS-CoV-2 B-Cell Epitopes Eliciting Neutralizing Antibodies.
    Poh CL; Yahaya AAAB; Cheong HT; Lim HX
    Methods Mol Biol; 2024; 2821():165-177. PubMed ID: 38997488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
    Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
    Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
    Tarke A; Coelho CH; Zhang Z; Dan JM; Yu ED; Methot N; Bloom NI; Goodwin B; Phillips E; Mallal S; Sidney J; Filaci G; Weiskopf D; da Silva Antunes R; Crotty S; Grifoni A; Sette A
    Cell; 2022 Mar; 185(5):847-859.e11. PubMed ID: 35139340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.
    Shrestha LB; Tedla N; Bull RA
    Front Immunol; 2021; 12():752003. PubMed ID: 34646276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies.
    Fox-Fisher I; Piyanzin S; Briller M; Oiknine-Djian E; Alfi O; Ben-Ami R; Peretz A; Neiman D; Ochana BL; Fridlich O; Drawshy Z; Klochendler A; Magenheim J; Share D; Avrahami R; Ribak Y; Talmon A; Rubin L; Milman N; Segev M; Feldman E; Tal Y; Shen-Orr SS; Glaser B; Shemer R; Wolf D; Dor Y
    Med; 2022 Jul; 3(7):468-480.e5. PubMed ID: 35716665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y
    EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
    [No Abstract]   [Full Text] [Related]  

  • 38. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike.
    van der Velden YU; Grobben M; Caniels TG; Burger JA; Poniman M; Oomen M; Rijnstra ES; Tejjani K; Guerra D; Kempers R; Stegmann T; van Gils MJ; Sanders RW
    Sci Rep; 2022 Mar; 12(1):3884. PubMed ID: 35273217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
    Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
    Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.